Lin BioScience, Inc.

Lin BioScience: Corporate Overview: Lin BioScience, Inc. (TPEx: 6696) is a drug development company established in 2016 focusing on advancing novel therapies and first-in-class treatments for unmet medical needs in various therapeutic areas such as ophthalmology, oncology, and metabolic diseases. Lin BioScience’s pipeline currently consists of four candidate drugs. LBS-008 treating dry age-related macular degeneration and Stargardt disease, and LBS-009 treating nonalcoholic steatohepatitis are developed by its subsidiary Belite Bio Inc. (Nasdaq: BLTE). LBS-007 treating acute leukemias and solid tumors, and LBS-002 treating glioblastoma and the metastasis are developed by Lin BioScience, inc..

MANAGEMENT TEAM: Lin BioScience is led by a management team with experienced background and talents in new drug development to research and develop breakthrough therapeutics and provide promises to patients who suffer from severe diseases.

Tom LinMBA MMed PhD(Med) Chairman: Dr. Tom Lin (Yu-Hsin Lin) is the Founder and Chairman of Lin BioScience, Inc. and Belite Bio (Nasdaq: BLTE). Prior to founding Lin BioScience and Belite Bio, Dr. Lin was executive officers of several biotech companies and has successful track records in taking biotech start-up companies public, including Lin BioScience, Inc. and Belite Bio, and has a vast clinical and drug development experience in cardiovascular, oncology, immuno-oncology, autoimmune and anti-inflammatory therapeutic areas.

Dr. Lin received his master’s degree in Medicine and PhD in Medicine from University of Sydney, and his MBA from Columbia University, London Business School, and University of Hong Kong.

Irene WangPhD MBA President & CSO: Dr. Irene Wang serves as President and Chief Scientific Officer of Lin BioScience since 2022. She joined Lin BioScience as a founding employee in 2016 as Director of Research & Development and promoted to Chief Scientific Officer since 2018. She is experienced in preclinical and clinical development in a wide range of therapeutic areas, including oncology, ophthalmology, and cardiovascular diseases. Prior to joining Lin BioScience, Dr. Wang served as Director of Research & Development for biotechnology start-ups and responsible for CMC, Preclinical & Pharma/tox, Companion Diagnostics, Clinical & Bioassays and global Clinical Trial & Regulatory submissions.

Dr. Wang received a Bachelor of Science in Chemistry, Ph.D. in Biological Sciences from National Taiwan University, and her MBA degree in University of California, San Diego. She was a postdoctoral fellow at Scripps Research Institute.

Yvonne Chen COO: Miss Yvonne Chen joined Lin BioScience as a founding employee in 2016 as Director of Clinical Operations and is serving as the Chief Operating Officer of Lin BioScience. Miss Chen has vast experience in clinical trial management and regulatory submissions with over 50 studies in various indications, ranging from Phase 1 to global Phase 3 studies. Prior to joining Lin BioScience, Miss Chen served as Global Project Lead, Project Manager, Clinical Operations Manager, Clinical Quality Manager and Clinical Research Associate in Pfizer Taiwan and biotechnology companies.

Miss Chen is a certified pharmacist and received a Bachelor of Science in Pharmacy and her master’s degree in Medicinal Chemistry from National Taiwan University.

Serena Chen CFO: Miss Serena Chen joined Lin BioScience as a founding employee in 2016 as Manager of Finance and Accounting Department and is serving as the CFO of Lin BioScience responsible for managing accounting, finance, budget, stock affairs, investor relations and corporate communications. Prior to joining Lin BioScience Inc., Miss Chen worked as finance manager in a Taiwan biotech company (2015-2016) and as assistant manager of audit department in Deloitte Taiwan (2009-2014). Miss Chen has had solid experiences in initial public offering (IPO) and auditing of listed companies.

Miss Chen is a certified public accountant (CPA) and received her master’s degree in accounting from National Taipei University.